- Conditions
- Breast Cancer
- Interventions
- Capecitabine, [177Lu]Lu-NeoB, [68Ga]Ga-NeoB
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Newport Beach, California • Rochester, Minnesota + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the local directory fallback.
- Conditions
- Metastatic Neuroendocrine Prostate Cancer
- Interventions
- Antiemetics & antinauseants, GnRH antagonists, Gonadotropin-releasing hormone (GnRH) analogues, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Metoclopramide, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, [177Lu]Lu-PSMA-617, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [68Ga]Ga-PSMA-11
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska • New York, New York
- Conditions
- Newly Diagnosed and Recurrent Glioblastoma
- Interventions
- Temozolomide, [177Lu]Lu-NeoB, [68Ga]Ga-NeoB
- Other · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, Goserelin, Ribociclib, [177Lu]Lu-NeoB, [68Ga]Ga-NeoB
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Houston, Texas